Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Sells $51,520.00 in Stock

Share on StockTwits

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 1,000 shares of the stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $51.52, for a total transaction of $51,520.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

NASDAQ TRHC opened at $53.43 on Monday. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of 157.15 and a beta of 1.69. Tabula Rasa HealthCare Inc has a 52-week low of $40.86 and a 52-week high of $91.16.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The company had revenue of $60.96 million for the quarter, compared to analyst estimates of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. Research analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 EPS for the current fiscal year.

A number of research firms recently issued reports on TRHC. Cantor Fitzgerald reiterated a “buy” rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a research note on Thursday, February 28th. Oppenheimer lowered their target price on shares of Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 6th. BidaskClub upgraded shares of Tabula Rasa HealthCare from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 9th. First Analysis upgraded shares of Tabula Rasa HealthCare from an “outperform” rating to a “strong-buy” rating and set a $58.33 target price on the stock in a research note on Monday, March 11th. Finally, Guggenheim began coverage on shares of Tabula Rasa HealthCare in a research note on Wednesday, April 17th. They issued a “neutral” rating and a $58.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $82.12.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Tabula Rasa HealthCare by 1.6% in the 4th quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock worth $165,831,000 after purchasing an additional 40,174 shares during the last quarter. Fiera Capital Corp acquired a new stake in Tabula Rasa HealthCare in the 4th quarter worth $2,268,000. Polar Capital LLP acquired a new stake in Tabula Rasa HealthCare in the 4th quarter worth $3,953,000. Nicholas Company Inc. grew its position in Tabula Rasa HealthCare by 6.5% in the 4th quarter. Nicholas Company Inc. now owns 77,485 shares of the company’s stock worth $4,940,000 after purchasing an additional 4,750 shares during the last quarter. Finally, Summit Creek Advisors LLC acquired a new stake in Tabula Rasa HealthCare in the 1st quarter worth $2,885,000. Institutional investors own 86.68% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: Candlestick

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Lowers News  to Underweight
JPMorgan Chase & Co. Lowers News to Underweight
Bayerische Motoren Werke  Receives Buy Rating from Credit Suisse Group
Bayerische Motoren Werke Receives Buy Rating from Credit Suisse Group
$86.04 Million in Sales Expected for Pennsylvania R.E.I.T.  This Quarter
$86.04 Million in Sales Expected for Pennsylvania R.E.I.T. This Quarter
$196.88 Million in Sales Expected for Cadence Bancorp  This Quarter
$196.88 Million in Sales Expected for Cadence Bancorp This Quarter
Bonterra Energy  Sets New 12-Month Low Following Analyst Downgrade
Bonterra Energy Sets New 12-Month Low Following Analyst Downgrade
Applied Materials, Inc.  Expected to Post Quarterly Sales of $3.53 Billion
Applied Materials, Inc. Expected to Post Quarterly Sales of $3.53 Billion


 
© 2006-2019 Zolmax.